{
  "report_rows": [
    {
      "kpi": "Adj. EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$4.92 vs. cons $4.778",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.74B vs. cons $3.714B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "BLS Quarterly Book-to-Bill (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~1.07x vs. cons 1.12x",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Adj. EPS (FY26)",
      "prediction": "BETTER",
      "answer": "guide ~$17.90-$18.55 (mid ~$18.23) vs. cons $18.052",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Revenue Growth (FY26)",
      "prediction": "BETTER",
      "answer": "guide ~5.2%-6.3% (mid ~$14.76B) vs. cons $14.716B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "BLS/Early Dev H2 Commentary (FY26)",
      "prediction": "UNCHANGED",
      "answer": "reiterate H2 improvement; streamlining complete; cautious B2B recovery pace",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 0.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.5,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE \u2014 positive EPS/guide revisions offset by BLS B2B miss; no multiple expansion from stretched pre-run",
  "day5_confidence": "MEDIUM"
}